As a leader and expert in the field of non-IgG therapeutic antibody development, Creative Biolabs is able to provide state-of-the-art technologies to meet any requirement of our customers. We have successfully completed a series of challenges in the past years. In particular, we have established an advanced non-IgG antibodies (mainly IgA, IgM, and IgE) based therapeutic antibodies discovery platform which enables us to offer a series of high-quality therapeutic IgM antibody discovery services for the diagnosis of a full range of diseases.
Our Service
Creative Biolabs offers a comprehensive range of services for the discovery and development of therapeutic IgM antibodies. Our platform is built on decades of expertise in non-IgG antibody research and is supported by state-of-the-art technologies designed to meet the unique challenges of IgM antibody production. Our services include the generation of custom IgM antibodies against a wide variety of disease targets, including tumors, infections, and inflammatory conditions. All antibodies are rigorously validated using a panel of industry-standard assays, such as Western Blotting, enzyme-linked immunosorbent assays (ELISA), and lateral flow assays (LFA). These technologies enable precise characterization of IgM antibody binding properties and functional activities, ensuring that each antibody meets the highest quality standards.
Service Process
Highlights
-
Expertise in Non-IgG Antibodies
Creative Biolabs is one of the few CROs with a deep understanding of non-IgG antibodies. With years of research dedicated to the development of IgA, IgM, and IgE therapeutic antibodies, our team has accumulated extensive expertise in overcoming the challenges associated with these isotypes. -
Custom Solutions
Our IgM antibody discovery services are highly customizable, allowing us to tailor each project to the unique needs of our clients. Whether the goal is diagnostic development or therapeutic intervention, Creative Biolabs delivers bespoke solutions that maximize the potential of IgM antibodies. -
Advanced Validation Platforms
We utilize a variety of advanced technology platforms to validate the performance of IgM antibodies, ensuring that they meet the highest standards of efficacy and reliability. From Western Blotting to ELISA and LFA, our validation services are designed to provide clients with comprehensive data on antibody performance. -
Proven Track Record
Creative Biolabs has a proven track record in developing IgM antibodies for a range of applications, including cancer diagnostics, infectious disease treatment, and inflammation regulation. Our successful completion of numerous projects demonstrates our commitment to excellence in antibody discovery.
Background
The immunoglobulin M (IgM) antibody is the largest isotype among the five immunoglobulin classes and is characterized by a unique μ-heavy chain. Typically, the monomeric IgM antibody consists of five or six domains, with each domain comprising two heavy (H) chains and two light (L) chains. It is generally produced either as a monomer attached to the B cell membrane or as a secreted pentamer. Due to their size, IgM antibodies are unable to cross the placenta; however, they can quickly initiate an immune response against infections by binding to specific antigens. Recent studies have highlighted the critical role of IgM antibodies in mediating B cell activation and triggering the classical pathway of the complement system. Additionally, they are involved in blood clotting reactions and the primary immune response of red blood cells. IgM levels surge in response to the initial invasion of antigens, and the ratio of IgG to IgM serves as a negative correlation that can be used to evaluate infection status. Consequently, IgM antibodies have emerged as valuable tools in diagnostics and potential therapeutic agents in both laboratory and clinical settings.
Fig. 1 Schematic diagram of an (IgM) antibody pentamer and hexamer.1
Beyond their established protective roles in the immune system, recent investigations have also underscored other potential functions and properties of IgM antibodies, including apoptotic and altered cell clearance, inflammation regulation, and the modulation of autoreactive antibodies. Notably, IgM antibodies have been identified as effective early diagnostic tools for various diseases, including cancers and infections. Research has confirmed the significant role of IgM antibodies in the early detection, elimination, and clearance of tumor-associated cells. Furthermore, studies indicate that IgM antibodies can eradicate tumor cells through several mechanisms, such as inducing cell apoptosis and activating the complement pathway. As a result, multiple IgM monoclonal antibodies have been developed and are now widely utilized in the diagnosis of various carcinomas, including monoclonal IgM antibodies PAM-1, FC-2.15, the natural IgM antibody SC-1, and the natural IgM antibody SAM-6.
FAQs
Q1: What are the advantages of IgM antibodies compared to IgG antibodies?
A: IgM antibodies exhibit higher avidity due to their multivalent structure, making them highly effective at binding low-density antigens. They also induce more robust complement-dependent cytotoxicity (CDC) and can trigger stronger immune responses compared to IgG antibodies.
Q2: How does Creative Biolabs overcome the challenges of IgM antibody production?
A: Creative Biolabs has developed proprietary expression systems and purification techniques specifically designed for IgM antibodies. These innovations allow us to produce IgM antibodies in large quantities while maintaining their stability and functionality.
Q3: Can IgM antibodies be used for diagnostic applications?
A: Yes, IgM antibodies have been successfully used as diagnostic tools, particularly for detecting early-stage infections and cancers. Their ability to bind antigens at low concentrations makes them highly sensitive diagnostic agents.
Q4: How can I inquire about Creative Biolabs' IgM antibody services?
A: To inquire about our IgM antibody services, please fill out our online inquiry form. We provide tailored quotes based on your project's scale, complexity, and customization requirements.
Resource
A Brief Introduction to Non-IgG Antibody - Creative Biolabs 
A Brief Introduction to Non-IgG Antibody -
Creative Biolabs
As one of the top CROs in the field of antibody development for disease therapy, Creative Biolabs has focused on non-IgG antibody discovery for years and has successfully accomplished numerous challenging projects in this field. We can offer high-quality target construction and custom services for our clients. If you are interested in our services, please contact us or send us an inquiry.
Reference
- Keyt, Bruce A., et al. "Structure, function, and therapeutic use of IgM antibodies." Antibodies 9.4 (2020): 53. Distributed under the Open Access license CC BY 4.0, without modification.
KINDLY NOTE
!! For Research Use Only. Our products and services are NOT intended for diagnostic or therapeutic applications.
